Comparison of nonsynonymous mutations
| Gene . | Mutants observed . | |||
|---|---|---|---|---|
| Present analysis, N = 133 myeloma tumor samples . | Previous study, N = 38 myeloma tumor samples . | |||
| n . | % (95% CI) . | n . | % (95% CI) . | |
| RAS/RAF* | 61 | 45.9 (37-54.3) | 20 | 52.6 (37-68.5) |
| RAS* | 58 | 43.6 (35-52.0) | 19 | 50.0 (34-65.9) |
| KRAS | 32 | 24.1 (17-31.3) | 10 | 26.3 (12-40.3) |
| NRAS | 26 | 19.5 (13-26.3) | 9 | 23.7 (10-37.2) |
| TP53 | 3 | 2.3 (0-4.8) | 3 | 7.9 (0-16.5) |
| BRAF | 3 | 2.3 (0-4.8) | 1 | 2.6 (0-7.7) |
| PDGFRA† | 3 | 2.3 (0-4.8) | 0 | 0 |
| JAK3† | 2 | 1.5 (0-3.6) | 0 | 0 |
| EGFR | 1 | 0.8 (0-2.2) | 1 | 2.6 (0-7.7) |
| APC† | 1 | 0.8 (0-2.2) | 0 | 0 |
| CDKN2A† | 1 | 0.8 (0-2.2) | 0 | 0 |
| CTNNB1† | 1 | 0.8 (0-2.2) | 0 | 0 |
| FGFR3† | 1 | 0.8 (0-2.2) | 0 | 0 |
| KIT† | 1 | 0.8 (0-2.2) | 0 | 0 |
| PTEN† | 1 | 0.8 (0-2.2) | 0 | 0 |
| STK11† | 1 | 0.8 (0-2.2) | 0 | 0 |
| ERBB3 | 0 | 0 | 1 | 2.6 (0-7.7) |
| FGFR2 | 0 | 0 | 1 | 2.6 (0-7.7) |
| JAK2 | 0 | 0 | 1 | 2.6 (0-7.7) |
| PTPN11 | 0 | 0 | 1 | 2.6 (0-7.7) |
| RB1 | 0 | 0 | 1 | 2.6 (0-7.7) |
| Gene . | Mutants observed . | |||
|---|---|---|---|---|
| Present analysis, N = 133 myeloma tumor samples . | Previous study, N = 38 myeloma tumor samples . | |||
| n . | % (95% CI) . | n . | % (95% CI) . | |
| RAS/RAF* | 61 | 45.9 (37-54.3) | 20 | 52.6 (37-68.5) |
| RAS* | 58 | 43.6 (35-52.0) | 19 | 50.0 (34-65.9) |
| KRAS | 32 | 24.1 (17-31.3) | 10 | 26.3 (12-40.3) |
| NRAS | 26 | 19.5 (13-26.3) | 9 | 23.7 (10-37.2) |
| TP53 | 3 | 2.3 (0-4.8) | 3 | 7.9 (0-16.5) |
| BRAF | 3 | 2.3 (0-4.8) | 1 | 2.6 (0-7.7) |
| PDGFRA† | 3 | 2.3 (0-4.8) | 0 | 0 |
| JAK3† | 2 | 1.5 (0-3.6) | 0 | 0 |
| EGFR | 1 | 0.8 (0-2.2) | 1 | 2.6 (0-7.7) |
| APC† | 1 | 0.8 (0-2.2) | 0 | 0 |
| CDKN2A† | 1 | 0.8 (0-2.2) | 0 | 0 |
| CTNNB1† | 1 | 0.8 (0-2.2) | 0 | 0 |
| FGFR3† | 1 | 0.8 (0-2.2) | 0 | 0 |
| KIT† | 1 | 0.8 (0-2.2) | 0 | 0 |
| PTEN† | 1 | 0.8 (0-2.2) | 0 | 0 |
| STK11† | 1 | 0.8 (0-2.2) | 0 | 0 |
| ERBB3 | 0 | 0 | 1 | 2.6 (0-7.7) |
| FGFR2 | 0 | 0 | 1 | 2.6 (0-7.7) |
| JAK2 | 0 | 0 | 1 | 2.6 (0-7.7) |
| PTPN11 | 0 | 0 | 1 | 2.6 (0-7.7) |
| RB1 | 0 | 0 | 1 | 2.6 (0-7.7) |
Comparison of nonsynonymous mutations detected by Sequenom screening of 133 myeloma tumor samples in the present analysis, and in a previous study7 of 38 myeloma tumor samples.
RAS/RAF and RAS are aggregate categories including KRAS, NRAS, and BRAF mutants, and KRAS and NRAS mutants, respectively.
Mutants detected in the present study that were not reported in the previous study by Chapman et al7 and were absent and/or rarely observed in previous reports of myeloma tumor genetic profiling.